Galderma, the brand behind fillers like Restylane, Dysport and Sculptra Aesthetic, announced today the FDA approval of two new fillers to the Restylane category: Restylane Refyne and Restylane Defyne.

Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in ...

There's a new filler in town (actually, two new fillers) and they're billed as the next big thing in the fight against laugh lines. Galderma, the pharmaceutical company behind injectables like ...

Results showed that 74% of Restylane Defyne-treated patients achieved significantly improved chin projection for up to 1 year. The Food and Drug Administration (FDA) has approved Restylane ® Defyne ...

Hyaluronic acid 20mg/mL, lidocaine 3mg/mL; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...

(MENAFN- PR Newswire) FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ -- Galderma announces that the U.S. Food and Drug Administration (FDA) has approved Restylane® Defyne for the augmentation and ...

The US Food and Drug Administration (FDA) has approved two new dermal fillers to improve the appearance of nasolabial fold (NLF) wrinkles in adults, the manufacturer Galderma has announced. Restylane ...

Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma's proprietary OBT designed to move in harmony with facial expressions while ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Restylane Defyne for mild to moderate chin retrusion augmentation in adults older than 21 ...

Galderma, the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT-based hyaluronic acid injectables ever authorized in Japan. The ...